BOSTON, Aug. 5, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today officially announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality. In her new capacity, Dr. Zalani serves on the Leadership Team and reports directly to Chairman, President & CEO Kurt Graves. The key new hire comes at a time when Intarcia is building out the company and 'rounding the corner' toward its first Phase 3 milestone later this year, with several others to follow in 2015. The role requires a proven leader with the ability to multi-task, to be results-oriented, to know how to avoid unnecessary risks, and the demonstrated ability to build highly productive and trust-based relationships with health authorities, partners, suppliers and other key stakeholders.
"We led a very competitive search for the person who would best meet the steep demands of our global regulatory and quality functions, and I'm delighted Intarcia prevailed as Sunita's choice out of several other simultaneous options she had," said Mr. Graves. "Sunita was our first choice almost immediately because of her proven leadership and operational experience in both large, and more recently, smaller biotech companies. She is a quick study, strategic, and impressively effective in a lean company environment. She gets difficult things done, and she gets them done extremely effectively and reliably. Her track record shows her to be a team leader with a 'gut grasp' of how to succeed in the biotech industry. Sunita also fits with our culture, our values, and the roll-up-your-sleeves energy required to be successful at Intarcia. This compatibility with our 'DNA' is vitally important. I'm confident that she will play a critical role in these exciting times as we move to strengthen the organization and build great relationships with health authorities and key part
|SOURCE Intarcia Therapeutics, Inc.|
Copyright©2014 PR Newswire.
All rights reserved